| Autor: |
Verschuuren, Erik A. M., Stevens, Servi J. C., Imhoff, Gustaaf W. van, Middeldorp, Jaap M., de Boer, Conny, Koëter, Gerard, The, Hauw T., van der Bij, Wim |
| Zdroj: |
Transplantation; January 2002, Vol. 73 Issue: 1 p100-104, 5p |
| Abstrakt: |
Rituximab, a humanized antiCD20 monoclonal antibody, is a promising new tool for the treatment of posttransplant lymphoproliferative disease PTLD, especially for patients transplanted with rejection prone transplants of vital organs, such as patients after lung transplantation. Thus far, no major complications have been described. We treated three lung transplant recipients with Rituximab because of PTLD. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
